Earendil Labs closed a $787 million financing round to accelerate an AI‑driven biologics pipeline spanning autoimmune disease and oncology. Founder and CEO Jian Peng said the capital lets the company "operate at a fundamentally different scale," enabling multiple programs to advance toward clinical testing and build a larger R&D organization. Investors include Dimension, Luminous Ventures and Sanofi. Earendil claims more than 40 programs across modalities such as bispecifics, T‑cell engagers and ADCs, with at least one program positioned for Phase 2. The round reinforces investor confidence in companies that combine generative AI with biologics engineering and underlines growing strategic partnerships between AI drug startups and multinational pharmas.